Sanofi's first big trial for top cancer drug ends in setback
One of Sanofi’s top late-stage prospects has failed its first major test in breast cancer, dimming blockbuster hopes even as the French drugmaker doubles down on oncology.
Sanofi had touted amcenestrant as a “potentially transformative” product. In the AMEERA-3 trial, though, it did not meet the primary endpoint of improving progression-free survival over endocrine treatment of physician’s choice.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 147,200+ biopharma pros reading Endpoints daily — and it's free.